• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

羟氯喹啉、瑞德西韦和四氢大麻酚的结构修饰化合物对严重急性呼吸综合征冠状病毒2主要蛋白酶的作用:COVID-19的一种可能希望——对接和分子动力学模拟研究

Structurally modified compounds of hydroxychloroquine, remdesivir and tetrahydrocannabinol against main protease of SARS-CoV-2, a possible hope for COVID-19: Docking and molecular dynamics simulation studies.

作者信息

Mishra Deepak, Maurya Radha Raman, Kumar Kamlesh, Munjal Nupur S, Bahadur Vijay, Sharma Sandeep, Singh Prashant, Bahadur Indra

机构信息

Department of Chemistry, SRM University, Delhi-NCR Sonepa t, Haryana 131029, India.

Department of Chemistry, Ramjas College, University of Delhi, University Enclave, Delhi 110007, India.

出版信息

J Mol Liq. 2021 Aug 1;335:116185. doi: 10.1016/j.molliq.2021.116185. Epub 2021 Apr 16.

DOI:10.1016/j.molliq.2021.116185
PMID:33879934
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8051003/
Abstract

Now a days, more than 200 countries faces the health crisis due to epidemiological disease COVID-19 caused by SARS-CoV-2 virus. It will cause a very high impact on world's economy and global health sector. Earlier the structure of main protease (M) protein was deposited in the RCSB protein repository. Hydroxychloroquine (HCQ) and remdesivir were found to effective in treatment of COVID-19 patients. Here we have performed docking and molecule dynamic (MD) simulation study of HCQ and remdesivir with M protein which gave promising results to inhibit M protein in SARS-CoV-2. On the basis of results obtained we designed structurally modified 18 novel derivatives of HCQ, remdesivir and tetrahydrocannabinol (THC) and carried out docking studies of all the derivatives. From the docking studies six molecules DK4, DK7, DK10, DK16, DK17 and DK19 gave promising results and can be use as inhibitor for M of SARS-CoV-2 to control COVID-19 very effectively. Further, molecular dynamics simulation of one derivative of HCQ and one derivative of tetrahydrocannabinol showing excellent docking score was performed along with the respective parent molecules. The two derivatives gave excellent docking score and higher stability than the parent molecule as validated with molecular dynamics (MD) simulation for the binding affinities towards M of SARS-CoV-2 thus represented as strong inhibitors at very low concentration.

摘要

如今,200 多个国家面临由严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)引发的 COVID-19 这一流行病学疾病带来的健康危机。它将对世界经济和全球卫生部门造成极大影响。此前,主要蛋白酶(M)蛋白的结构已存入 RCSB 蛋白质数据库。已发现羟氯喹(HCQ)和瑞德西韦对治疗 COVID-19 患者有效。在此,我们对 HCQ 和瑞德西韦与 M 蛋白进行了对接和分子动力学(MD)模拟研究,结果显示有望抑制 SARS-CoV-2 中的 M 蛋白。基于所得结果,我们设计了 HCQ、瑞德西韦和四氢大麻酚(THC)的 18 种结构修饰新型衍生物,并对所有衍生物进行了对接研究。对接研究表明,DK4、DK7、DK10、DK16、DK17 和 DK19 这六个分子显示出良好效果,可作为 SARS-CoV-2 的 M 蛋白抑制剂非常有效地控制 COVID-19。此外,对 HCQ 的一种衍生物和四氢大麻酚的一种衍生物进行了分子动力学模拟,这两种衍生物在对接评分方面表现出色,同时还对各自的母体分子进行了模拟。正如通过分子动力学(MD)模拟验证的那样,这两种衍生物对 SARS-CoV-2 的 M 蛋白具有优异的对接评分和比母体分子更高的稳定性,因此在极低浓度下可作为强效抑制剂。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b163/8051003/202df01c36b0/gr17_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b163/8051003/533e10b71104/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b163/8051003/e15ab4e8bf66/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b163/8051003/03d185af9f72/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b163/8051003/6f9d80f36e42/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b163/8051003/996b954fb72e/gr5_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b163/8051003/edffb915c356/gr6_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b163/8051003/3178a238bf93/gr7_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b163/8051003/81d147c6cde7/gr8_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b163/8051003/32e7513b2873/gr9_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b163/8051003/e665bb683b0a/gr10_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b163/8051003/a5ac377035e3/gr11_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b163/8051003/b7cc0cd5825b/gr12_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b163/8051003/597f2611464c/gr13_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b163/8051003/ed6919b4da45/gr14_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b163/8051003/9e34af9229b3/gr15_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b163/8051003/69cbc5bb1065/gr16_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b163/8051003/202df01c36b0/gr17_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b163/8051003/533e10b71104/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b163/8051003/e15ab4e8bf66/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b163/8051003/03d185af9f72/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b163/8051003/6f9d80f36e42/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b163/8051003/996b954fb72e/gr5_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b163/8051003/edffb915c356/gr6_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b163/8051003/3178a238bf93/gr7_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b163/8051003/81d147c6cde7/gr8_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b163/8051003/32e7513b2873/gr9_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b163/8051003/e665bb683b0a/gr10_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b163/8051003/a5ac377035e3/gr11_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b163/8051003/b7cc0cd5825b/gr12_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b163/8051003/597f2611464c/gr13_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b163/8051003/ed6919b4da45/gr14_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b163/8051003/9e34af9229b3/gr15_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b163/8051003/69cbc5bb1065/gr16_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b163/8051003/202df01c36b0/gr17_lrg.jpg

相似文献

1
Structurally modified compounds of hydroxychloroquine, remdesivir and tetrahydrocannabinol against main protease of SARS-CoV-2, a possible hope for COVID-19: Docking and molecular dynamics simulation studies.羟氯喹啉、瑞德西韦和四氢大麻酚的结构修饰化合物对严重急性呼吸综合征冠状病毒2主要蛋白酶的作用:COVID-19的一种可能希望——对接和分子动力学模拟研究
J Mol Liq. 2021 Aug 1;335:116185. doi: 10.1016/j.molliq.2021.116185. Epub 2021 Apr 16.
2
Molecular docking, binding mode analysis, molecular dynamics, and prediction of ADMET/toxicity properties of selective potential antiviral agents against SARS-CoV-2 main protease: an effort toward drug repurposing to combat COVID-19.针对 SARS-CoV-2 主蛋白酶的选择性潜在抗病毒药物的分子对接、结合模式分析、分子动力学和 ADMET/毒性性质预测:药物再利用以对抗 COVID-19 的努力。
Mol Divers. 2021 Aug;25(3):1905-1927. doi: 10.1007/s11030-021-10188-5. Epub 2021 Feb 13.
3
validation of coumarin derivatives as potential inhibitors against Main Protease, NSP10/NSP16-Methyltransferase, Phosphatase and Endoribonuclease of SARS CoV-2.验证香豆素衍生物作为潜在抑制剂对 SARS-CoV-2 的主要蛋白酶、NSP10/NSP16-甲基转移酶、磷酸酶和内切核糖核酸酶的抑制作用。
J Biomol Struct Dyn. 2021 Nov;39(18):7306-7321. doi: 10.1080/07391102.2020.1808075. Epub 2020 Aug 24.
4
Natural Compounds as Inhibitors of SARS-CoV-2 Main Protease (3CLpro): A Molecular Docking and Simulation Approach to Combat COVID-19.天然化合物作为新型冠状病毒主要蛋白酶(3CLpro)的抑制剂:一种对抗新冠肺炎的分子对接和模拟方法
Curr Pharm Des. 2021;27(33):3577-3589. doi: 10.2174/1381612826999201116195851.
5
In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.基于药物再利用的分子对接和动力学模拟预测 SARS-CoV-2 主要蛋白酶的潜在抑制剂的计算机预测。
J Infect Public Health. 2020 Sep;13(9):1210-1223. doi: 10.1016/j.jiph.2020.06.016. Epub 2020 Jun 16.
6
Structural insight to hydroxychloroquine-3C-like proteinase complexation from SARS-CoV-2: inhibitor modelling study through molecular docking and MD-simulation study.从 SARS-CoV-2 中获得羟氯喹-3C 样蛋白酶复合物的结构见解:通过分子对接和 MD 模拟研究进行抑制剂建模研究。
J Biomol Struct Dyn. 2021 Nov;39(18):7322-7334. doi: 10.1080/07391102.2020.1804458. Epub 2020 Aug 10.
7
Design, synthesis and docking study of Vortioxetine derivatives as a SARS-CoV-2 main protease inhibitor.设计、合成和对接研究文拉法辛衍生物作为 SARS-CoV-2 主蛋白酶抑制剂。
Daru. 2022 Jun;30(1):139-152. doi: 10.1007/s40199-022-00441-z. Epub 2022 May 4.
8
Optimization Rules for SARS-CoV-2 M Antivirals: Ensemble Docking and Exploration of the Coronavirus Protease Active Site.SARS-CoV-2 M 抗病毒药物的优化规则:冠状病毒蛋白酶活性位点的整体对接和探索。
Viruses. 2020 Aug 26;12(9):942. doi: 10.3390/v12090942.
9
Targeting COVID-19 (SARS-CoV-2) main protease through active phytochemicals of ayurvedic medicinal plants - (Ashwagandha), (Giloy) and (Tulsi) - a molecular docking study.通过阿育吠陀药用植物( Ashwagandha )、( Giloy )和( Tulsi )的活性植物化学成分靶向 COVID-19 ( SARS-CoV-2 )主蛋白酶 - ( Ashwagandha )、( Giloy )和( Tulsi ) - 分子对接研究。
J Biomol Struct Dyn. 2022 Jan;40(1):190-203. doi: 10.1080/07391102.2020.1810778. Epub 2020 Aug 27.
10
In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection.计算机模拟研究阿奇霉素、氯喹和羟氯喹及其对 SARS-CoV-2 感染的潜在作用机制。
Int J Antimicrob Agents. 2020 Sep;56(3):106119. doi: 10.1016/j.ijantimicag.2020.106119. Epub 2020 Jul 30.

引用本文的文献

1
Molecular docking and molecular dynamics simulation studies of thiazole-coumarin and thiazole-triazole conjugates against M and ACE2 receptor for SARS COV-2.噻唑-香豆素和噻唑-三唑共轭物针对SARS-CoV-2的M和ACE2受体的分子对接及分子动力学模拟研究
In Silico Pharmacol. 2025 Jun 9;13(2):84. doi: 10.1007/s40203-025-00372-y. eCollection 2025.
2
A suitable drug structure for interaction with SARS-CoV-2 main protease between boceprevir, masitinib and rupintrivir; a molecular dynamics study.波普瑞韦、马西替尼和鲁平替韦之间与严重急性呼吸综合征冠状病毒2主要蛋白酶相互作用的合适药物结构;一项分子动力学研究
Arab J Chem. 2023 Sep;16(9):105051. doi: 10.1016/j.arabjc.2023.105051. Epub 2023 Jun 7.
3

本文引用的文献

1
Identification of potential molecules against COVID-19 main protease through structure-guided virtual screening approach.通过结构导向虚拟筛选方法鉴定抗新型冠状病毒主要蛋白酶的潜在分子。
J Biomol Struct Dyn. 2021 Jul;39(10):3662-3680. doi: 10.1080/07391102.2020.1768151. Epub 2020 May 20.
2
Structural and Evolutionary Analysis Indicate That the SARS-CoV-2 Mpro Is a Challenging Target for Small-Molecule Inhibitor Design.结构与进化分析表明,SARS-CoV-2 Mpro 是小分子抑制剂设计极具挑战性的靶标。
Int J Mol Sci. 2020 Apr 28;21(9):3099. doi: 10.3390/ijms21093099.
3
Current pharmacological treatments for COVID-19: What's next?
Potential inhibitory properties of structurally modified quercetin/isohamnetin glucosides against SARS-CoV-2 Mpro; molecular docking and dynamics simulation strategies.
结构修饰的槲皮素/异鼠李素糖苷对严重急性呼吸综合征冠状病毒2主蛋白酶的潜在抑制特性;分子对接和动力学模拟策略
Inform Med Unlocked. 2023;37:101167. doi: 10.1016/j.imu.2023.101167. Epub 2023 Jan 13.
4
Computer-aided discovery, design, and investigation of COVID-19 therapeutics.新冠病毒治疗药物的计算机辅助发现、设计与研究
Tzu Chi Med J. 2022 Mar 28;34(3):276-286. doi: 10.4103/tcmj.tcmj_318_21. eCollection 2022 Jul-Sep.
5
Methodology-Centered Review of Molecular Modeling, Simulation, and Prediction of SARS-CoV-2.基于方法的 SARS-CoV-2 分子建模、模拟和预测综述。
Chem Rev. 2022 Jul 13;122(13):11287-11368. doi: 10.1021/acs.chemrev.1c00965. Epub 2022 May 20.
6
The dolabellane diterpenes as potential inhibitors of the SARS-CoV-2 main protease: molecular insight of the inhibitory mechanism through computational studies.多拉贝烷二萜类化合物作为严重急性呼吸综合征冠状病毒2(SARS-CoV-2)主要蛋白酶的潜在抑制剂:通过计算研究对抑制机制的分子洞察
RSC Adv. 2021 Dec 10;11(62):39455-39466. doi: 10.1039/d1ra07584e. eCollection 2021 Dec 6.
7
Insights into the structure and dynamics of SARS-CoV-2 spike glycoprotein double mutant L452R-E484Q.对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)刺突糖蛋白双突变体L452R-E484Q的结构与动力学的见解
3 Biotech. 2022 Apr;12(4):87. doi: 10.1007/s13205-022-03151-0. Epub 2022 Mar 3.
8
In Silico Evaluation of Binding of 2-Deoxy-D-Glucose with Mpro of nCoV to Combat COVID-19.2-脱氧-D-葡萄糖与新型冠状病毒主蛋白酶结合的计算机模拟评估以对抗新冠病毒
Pharmaceutics. 2022 Jan 6;14(1):135. doi: 10.3390/pharmaceutics14010135.
9
Antimicrobial and Antiviral (SARS-CoV-2) Potential of Cannabinoids and : A Comprehensive Review.大麻素的抗菌和抗病毒(SARS-CoV-2)潜力:综合评价。
Molecules. 2021 Nov 28;26(23):7216. doi: 10.3390/molecules26237216.
10
Hunting the main protease of SARS-CoV-2 by plitidepsin: Molecular docking and temperature-dependent molecular dynamics simulations.利用普利替膦抑制 SARS-CoV-2 主蛋白酶:分子对接和温度依赖的分子动力学模拟。
Amino Acids. 2022 Feb;54(2):205-213. doi: 10.1007/s00726-021-03098-1. Epub 2021 Nov 22.
针对 COVID-19 的当前药理学治疗方法:下一步是什么?
Br J Pharmacol. 2020 Nov;177(21):4813-4824. doi: 10.1111/bph.15072. Epub 2020 May 15.
4
Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods.通过计算方法分析严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的治疗靶点并发现潜在药物
Acta Pharm Sin B. 2020 May;10(5):766-788. doi: 10.1016/j.apsb.2020.02.008. Epub 2020 Feb 27.
5
Structure of M from SARS-CoV-2 and discovery of its inhibitors.SARS-CoV-2 M 结构与抑制剂的发现
Nature. 2020 Jun;582(7811):289-293. doi: 10.1038/s41586-020-2223-y. Epub 2020 Apr 9.
6
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.羟氯喹和阿奇霉素治疗 COVID-19:一项开放标签非随机临床试验的结果。
Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20.
7
Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro.羟氯喹啉是氯喹毒性较低的衍生物,在体外可有效抑制严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染。
Cell Discov. 2020 Mar 18;6:16. doi: 10.1038/s41421-020-0156-0. eCollection 2020.
8
Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2.基于网络的2019新型冠状病毒(2019-nCoV/SARS-CoV-2)药物重新利用研究
Cell Discov. 2020 Mar 16;6:14. doi: 10.1038/s41421-020-0153-3. eCollection 2020.
9
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.一项关于氯喹治疗 COVID-19 的疗效和安全性的系统评价。
J Crit Care. 2020 Jun;57:279-283. doi: 10.1016/j.jcrc.2020.03.005. Epub 2020 Mar 10.
10
Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host-Virus Interaction, and Proposed Neurotropic Mechanisms.新型冠状病毒(COVID-19)感染中枢神经系统的证据:组织分布、宿主-病毒相互作用及潜在神经嗜性机制。
ACS Chem Neurosci. 2020 Apr 1;11(7):995-998. doi: 10.1021/acschemneuro.0c00122. Epub 2020 Mar 13.